The SIPA1 -313A>G polymorphism is associated with prognosis in inoperable non-small cell lung cancer

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 1273-1278

  Gdowicz Kłosok, Agnieszka ^a   Giglok, Monika ^a   Drosik, Anna ^a   Suwiński, Rafał ^a   Butkiewicz, Dorota ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Lung cancer; Polymorphism; Prognosis; SIPA1; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; NAVELBINE; PROTEIN; SIGNAL INDUCED PROLIFERATION ASSOCIATED 1 PROTEIN; UNCLASSIFIED DRUG; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NUCLEAR PROTEIN; SIPA1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; FEMALE; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RADIATION DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; AGED; CANCER STAGING; DISEASE FREE SURVIVAL; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; GTPASE-ACTIVATING PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84923785323     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2753-8     Document Type: Article

References (17)

1. Hunter KW, Crawford NP, Alsarraj J. Mechanisms of metastasis. Breast Cancer Res. 2008;10 Suppl 1:S2.
2. Kurachi H, Wada Y, Tsukamoto N, Maeda M, Kubota H, Hattori M, et al. Human SPA-1 gene product selectively expressed in lymphoid tissues is a specific GTPase-activating protein for Rap1 and Rap2. Segregate expression profiles from a rap1GAP gene product. J Biol Chem. 1997;272:28081–8.
3. Shimizu Y, Hamazaki Y, Hattori M, Doi K, Terada N, Kobayashi T, et al. SPA-1 controls the invasion and metastasis of human prostate cancer. Cancer Sci. 2011;102:828–36.
4. Ji K, Ye L, Toms AM, Hargest R, Martin TA, Ruge F, et al. Expression of signal-induced proliferation-associated gene 1 (SIPA1), a RapGTPase-activating protein, is increased in colorectal cancer and has diverse effects on functions of colorectal cancer cells. Cancer Genomics Proteomics. 2012;9:321–7.
5. Zhang Y, Gong Y, Hu D, Zhu P, Wang N, Zhang Q, et al. Nuclear SIPA1 activates integrin β1 promoter and promotes invasion of breast cancer cells. Oncogene. 2014. doi:10.1038/onc.2014.36.
6. Akervall JA, Jin Y, Wennerberg JP, Zatterstrom UK, Kjellen E, Mertens F, et al. Chromosomal abnormalities involving 11q13 are associated with poor prognosis in patients with squamous cell carcinoma of the head and neck. Cancer. 1995;76:853–9.
7. Brown LA, Johnson K, Leung S, Bismar TA, Benítez J, Foulkes WD, et al. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Breast Cancer Res Treat. 2010;121(2):347–54.
8. Brooks R, Kizer N, Nguyen L, Jaishuen A, Wanat K, Nugent E, et al. Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer. Gynecol Oncol. 2010;116:539–43.
9. Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H, Hunter KW. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res. 2006;8:R16.
10. Hsieh SM, Look MP, Sieuwerts AM, Foekens JA, Hunter KW. Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study. Breast Cancer Res. 2009;11:R75.
11. Hsieh SM, Smith RA, Lintell NA, Hunter KW, Griffiths LR. Polymorphisms of the SIPA1 gene and sporadic breast cancer susceptibility. BMC Cancer. 2009;9:331.
12. Pei R, Xu Y, Wei Y, Ouyang T, Li J, Wang T, et al. Association of SIPA1 545 C > T polymorphism with survival in Chinese women with metastatic breast cancer. Front Med. 2013;7:138–42.
13. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5—a population-based study. Lancet Oncol. 2014;15:23–34.
14. Xie C, Yang L, Yang X, Yang R, Li Y, Qiu F, et al. Sipa1 promoter polymorphism predicts risk and metastasis of lung cancer in Chinese. Mol Carcinog. 2013;52 Suppl 1:E110–7.
15. Gaudet MM, Hunter K, Pharoah P, Dunning AM, Driver K, Lissowska J, et al. Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis. Int J Cancer. 2009;124:1716–20.
16. Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet. 2005;37:1055–62.
17. Yi SM, Li GY. The association of SIPA1 gene polymorphisms with breast cancer risk: evidence from published studies. Tumor Biol. 2014;35:441–5.